Key facts
- AdvanCell’s last known valuation is $165.0M (Jun 2025).
- It has raised $132.3M; the latest was Grant ($18.0M) in Apr 2025.
- Notable investors include Catalio Capital Management, Morningside Group, SV Health Investors, Brandon Capital, Time BioVentures — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for AdvanCell
- ·The full record, as it builds
Funding rounds
No funding rounds for AdvanCell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AdvanCell
Operator of a radiopharmaceutical company intended for developing alpha therapies for cancer patients. The company develops alpha-emitting isotopes attached to molecules that deliver cytotoxic radiation directly to tumors at the molecular level to address the significant challenge in targeted therapy that is reliable and scalable to supply, enabling healthcare providers with safe and effective treatment for multiple forms of cancer.
- Sector
- Healthcare
- HQ
- Sydney, Australia
- Founded
- 2019
- Employees
- 76
- Website
- advancell.com.au/
- Ownership
- Privately Held (backing)
AdvanCell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AdvanCell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AdvanCell in its N-PORT filings yet. We sweep new filings monthly.